Targeting Rb signaling for GBM treatment is mainly through CDK4/6 inhibitor, which have shown a promising prospect in clinical application (Michaud et al., 2010; Olmez et al., 2017; Qi et al., 2017). The gene discussed is CDK4; the disease is glioblastoma.